Jovitta Jacob

1.0k citations

23 papers · 273 indexed · h-index 6

Hematology top 10%
- Chronic Myeloid Leukemia Treatments 11
- Acute Myeloid Leukemia Research 1
Public Health, Environmental and Occupational Health top 10%
- Acute Lymphoblastic Leukemia research 23
Oncology
- CAR-T cell therapy research 7
- Neutropenia and Cancer Infections 1
Pediatrics, Perinatology and Child Health
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 7
Genetics
- Chronic Lymphocytic Leukemia Research 14
Molecular Biology
- Cancer therapeutics and mechanisms 2

Co-authors: Nitin Jain Rebecca Garris Farhad Ravandi Elias Jabbour Koji Sasaki Hagop M. Kantarjian Guillermo Garcia‐Manero Tapan M. Kadia
Cited by: Hematology Public Health, Environmental and Occupational Health Oncology
Journals: Blood (11 papers)Journal of Clinical Oncology (5 papers)Cancer (2 papers)
Partner nations: United States

In The Last Decade

Jovitta Jacob

22 papers receiving 271 citations

Peers

Countries citing papers authored by Jovitta Jacob

Since Specialization

Citations

This map shows the geographic impact of Jovitta Jacob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jovitta Jacob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jovitta Jacob more than expected).

Fields of papers citing papers by Jovitta Jacob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jovitta Jacob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jovitta Jacob. The network helps show where Jovitta Jacob may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jovitta Jacob, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jovitta Jacob Line = papers co-authored together Jovitta Jacob links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Blood ·Jayastu Senapati,Elias Jabbour,Nicholas J. Short,Nitin Jain,Fadi Haddad,Tapan M. Kadia,Koji Sasaki,María del Rosario Cortés Carranza,Koichi Takahashi,Courtney D. DiNardo,Naval Daver,Guillermo Garcia‐Manero,Farhad Ravandi,Jovitta Jacob,Rebecca Garris,Hagop Kantarjian	2024	3
2	Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update Blood ·Jayastu Senapati,Elias Jabbour,Nitin Jain,Fadi Haddad,Guillermo Garcia-Manero,Maria da Glória Guará Tavares,Tapan M. Kadia,Farhad Ravandi,Koji Sasaki,Courtney D. DiNardo,Koichi Takahashi,Rebecca Garris,Jovitta Jacob,弘毅山本,Guillermo Montalban‐Bravo,Nicholas J. Short,H. Kantarjian	2024	3
3	Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial The Lancet Haematology ·Elias Jabbour,Nicholas J. Short,Jayastu Senapati,Nitin Jain,Xuelin Huang,Naval Daver,Courtney D. DiNardo,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia‐Manero,Guillermo Montalban‐Bravo,Koji Sasaki,Tapan M. Kadia,Joseph D. Khoury,Sa A. Wang,Fadi Haddad,Jovitta Jacob,Rebecca Garris,Farhad Ravandi,Hagop M. Kantarjian	2023	49
4	P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA HemaSphere ·Fadi Haddad,Elias Jabbour,Shafira Laila Sasqia,Nicholas J. Short,Lewis Nasr,Walid Macaron,Myriam Iliovits,Farhad Ravandi,Nitin Jain,Tapan M. Kadia,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Jovitta Jacob,Е.О. Старцева,Christopher Loiselle,Anna Milton,Juan J. Rivera,Rebecca Garris,Hagop Kantarjian	2023	1
5	S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL HemaSphere ·Fadi Haddad,Elias Jabbour,Shafira Laila Sasqia,Nicholas J. Short,Walid Macaron,Myriam Iliovits,Lewis Nasr,Nitin Jain,Luisa San Emeterio,Koji Sasaki,Farhad Ravandi,Partow Kebriaei,Xuelin Huang,Guillermo Garcia‐Manero,Tapan M. Kadia,Sa A. Wang,Jovitta Jacob,Rebecca Garris,Susan O’Brien,Hagop M. Kantarjian	2023	3
6	Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. Journal of Clinical Oncology ·Lewis Nasr,Nicholas J. Short,Jayastu Senapati,弘毅山本,Nitin Jain,Marina Konopleva,Walid Macaron,Farhad Ravandi,Courtney D. DiNardo,Koji Sasaki,Alessandra Ferrajoli,Stephanie M. Bollard,Myriam Iliovits,Jovitta Jacob,Siti Khofifah Hanif,Anna Milton,Christopher Loiselle,Rebecca Garris,Hagop M. Kantarjian,Elias Jabbour	2023	2
7	Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial. Journal of Clinical Oncology ·Y. Y. Lee,Elias Jabbour,Fadi Haddad,Nicholas J. Short,Lewis Nasr,Walid Macaron,Myriam Iliovits,Farhad Ravandi,Nitin Jain,Tapan M. Kadia,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Jovitta Jacob,Е.О. Старцева,Christopher Loiselle,Anna Milton,Juan J. Rivera,Rebecca Garris,Hagop M. Kantarjian	2023	1
8	Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Blood ·Alexandar M. Liguori-Schremp,Elias Jabbour,Fadi Haddad,Nicholas J. Short,Nitin Jain,Tapan M. Kadia,Naval Daver,Gautam Borthakur,Lewis Nasr,Courtney D. DiNardo,Myriam Iliovits,Jovitta Jacob,Е.О. Старцева,Christopher Loiselle,Anna Milton,Juan J. Rivera,Rebecca Garris,Farhad Ravandi,Hagop M. Kantarjian	2023	3
9	A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia Blood ·Jayastu Senapati,Nicholas J. Short,Yesid Alvarado,Jan A. Burger,Nitin Jain,Marina Konopleva,Farhad Ravandi,Courtney D. DiNardo,Lucia Masárová,Koji Sasaki,Philip A. Thompson,Alessandra Ferrajoli,Jovitta Jacob,Siti Khofifah Hanif,Anna Milton,Christopher Loiselle,Rebecca Garris,Hagop Kantarjian,Elias Jabbour	2022	5
10	Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia SSRN Electronic Journal ·Hagop M. Kantarjian,Nitin Jain,Koji Sasaki,Elias Jabbour,Fadi Haddad,Sanam Loghavi,Rashmi Kanagal‐Shamanna,Jeffrey L. Jorgensen,Issa F. Khouri,Partow Kebriaei,Yesid Alvarado,Tapan M. Kadia,Shilpa Paul,Guillermo Garcia‐Manero,Bouthaina S. Dabaja,Musa Yılmaz,Jovitta Jacob,Rebecca Garris,Susan O’Brien,Farhad Ravandi	2022	2
11	Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology ·Walid Macaron,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Nitin Jain,Tapan M. Kadia,Fadi Haddad,弘毅山本,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Marina Konopleva,William G. Wierda,Jovitta Jacob,Е.О. Старцева,Christopher Loiselle,Anna Milton,Juan J. Rivera,Rebecca Garris,Elias Jabbour	2022	5
12	A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia Blood ·Nicholas J. Short,Hagop M. Kantarjian,Yesid Alvarado,Jan A. Burger,Nitin Jain,Marina Konopleva,Farhad Ravandi,Courtney D. DiNardo,Lucia Masárová,Koji Sasaki,Philip A. Thompson,Alessandra Ferrajoli,Jovitta Jacob,Anna Milton,Rebecca Garris,Elias Jabbour	2021	2
13	Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis Cancer ·Elias Jabbour,Koji Sasaki,Farhad Ravandi,Nicholas J. Short,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Jörge E. Cortes,Ghayas C. Issa,Jovitta Jacob,Monica Kwari,Philip A. Thompson,Rebecca Garris,Naveen Pemmaraju,Musa Yılmaz,Susan O’Brien,Hagop M. Kantarjian	2019	66
14	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage Cancer ·Elias Jabbour,Koji Sasaki,Farhad Ravandi,Xuelin Huang,Nicholas J. Short,Maria Khouri,Partow Kebriaei,Jan A. Burger,Joseph D. Khoury,Jeffrey L. Jorgensen,Nitin Jain,Marina Konopleva,Guillermo Garcia‐Manero,Tapan M. Kadia,Jörge E. Cortes,Jovitta Jacob,Kathryn Montalbano,Rebecca Garris,Susan O’Brien,Hagop M. Kantarjian	2018	76
15	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis Blood ·Koji Sasaki,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Maria Khouri,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Ghayas C. Issa,Jovitta Jacob,Rebecca Garris,Musa Yılmaz,Philip A. Thompson,T. J. Histen,Naveen Pemmaraju,Jörge E. Cortes,Susan O’Brien,Elias Jabbour	2018	2
16	Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology ·Rita Assi,Hagop M. Kantarjian,Farhad Ravandi,Susan O’Brien,Partow Kebriaei,Deborah A. Thomas,Guillermo Garcia‐Manero,Issa F. Khouri,Richard E. Champlin,Tapan M. Kadia,Jörge E. Cortes,Nitin Jain,Marina Konopleva,Diane M. Flynn,Zeev Estrov,Koichi Takahashi,Koji Sasaki,Jovitta Jacob,Rebecca Garris,Elias Jabbour	2017	1
17	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial Blood ·Koji Sasaki,Elias Jabbour,Susan O’Brien,Farhad Ravandi,Deborah A. Thomas,Guillermo Garcia‐Manero,Naval Daver,Gautam Borthakur,Nitin Jain,Marina Konopleva,Nicholas J. Short,Naveen Pemmaraju,Yesid Alvarado,Jovitta Jacob,Rebecca Garris,Philip A. Thompson,Jörge E. Cortes,Hagop M. Kantarjian	2016	17
18	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin Blood ·Jad Chahoud,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Koji Sasaki,Tapan M. Kadia,Jörge E. Cortes,Maria Khouri,Farhad Ravandi,L. Tang,Alessandra Ferrajoli,Jovitta Jacob,Naveen Pemmaraju,Naval Daver,Rebecca Garris,Elias Jabbour	2015	2
19	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL) Blood ·Elias Jabbour,Susan O’Brien,Koji Sasaki,Deborah A. Thomas,Guillermo Garcia‐Manero,Farhad Ravandi,Gautam Borthakur,Nitin Jain,Marina Konopleva,Jovitta Jacob,Rebecca Garris,Jörge E. Cortes,Hagop M. Kantarjian	2015	15
20	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) Blood ·Koji Sasaki,Hagop M. Kantarjian,Susan O’Brien,Deborah A. Thomas,Farhad Ravandi,Guillermo Garcia‐Manero,Tapan M. Kadia,Nitin Jain,Marina Konopleva,Zeev Estrov,Koichi Takahashi,Maria Khouri,Jovitta Jacob,Rebecca Garris,Jörge E. Cortes,Elias Jabbour	2015	11

About Jovitta Jacob

Jovitta Jacob is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health, having authored 23 papers that have together received 273 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (23 papers), Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (11 papers), CAR-T cell therapy research (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Cancer therapeutics and mechanisms (2 papers), Acute Myeloid Leukemia Research (1 paper) and Neutropenia and Cancer Infections (1 paper). The work is most often cited by research in Hematology (141 citations), Public Health, Environmental and Occupational Health (233 citations) and Oncology (180 citations). Jovitta Jacob has collaborated with scholars based in United States. Frequent co-authors include Nitin Jain, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Tapan M. Kadia, Nicholas J. Short and Marina Konopleva. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, HemaSphere and The Lancet Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact